Aurinia Pharmaceuticals Inc. (AUPH) climbed 7.52% to $14.16, up $0.99, after it reported third-quarter 2025 results showing total revenue of $73.5 million - up 8 percent year-over-year and net product sales of its lupus-nephritis therapy LUPKYNIS at $70.6 million, up 27 percent year-over-year.
The company also raised its full-year 2025 guidance for total revenue to a range of $275 million-$280 million and net product sales of $265 million-$270 million, citing growing demand following updated treatment guidelines.
On the day of the release, AUPH opened near $13.50, reached a high of $14.30, and closed at $14.16, with trading volume markedly above its average. The stock's 52-week range is approximately $11.50 - $17.50.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.